Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC

BACKGROUND: In the BEACON CRC study (NCT02928224), encorafenib plus cetuximab with binimetinib {9.3 versus 5.9 months; hazard ratio (HR) [95% confidence interval (CI)]: 0.60 [0.47-0.75]} or without binimetinib [9.3 versus 5.9 months; HR (95% CI): 0.61 (0.48-0.77)] significantly improved overall surv...

Descripción completa

Detalles Bibliográficos
Autores principales: Kopetz, S., Grothey, A., Van Cutsem, E., Yaeger, R., Wasan, H., Yoshino, T., Desai, J., Ciardiello, F., Loupakis, F., Hong, Y.S., Steeghs, N., Guren, T.K., Arkenau, H.-T., Garcia-Alfonso, P., Belani, A., Zhang, X., Tabernero, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271477/
https://www.ncbi.nlm.nih.gov/pubmed/35653981
http://dx.doi.org/10.1016/j.esmoop.2022.100477

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271477/
https://www.ncbi.nlm.nih.gov/pubmed/35653981
http://dx.doi.org/10.1016/j.esmoop.2022.100477

Ejemplares similares